SG Americas Securities LLC Grows Stock Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

SG Americas Securities LLC lifted its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 4.3% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 40,082 shares of the company’s stock after purchasing an additional 1,659 shares during the quarter. SG Americas Securities LLC’s holdings in IDEXX Laboratories were worth $16,572,000 at the end of the most recent quarter.

Several other institutional investors have also recently modified their holdings of IDXX. International Assets Investment Management LLC grew its holdings in shares of IDEXX Laboratories by 52,746.0% during the 3rd quarter. International Assets Investment Management LLC now owns 528,460 shares of the company’s stock valued at $2,669,890,000 after purchasing an additional 527,460 shares during the last quarter. Assenagon Asset Management S.A. boosted its position in IDEXX Laboratories by 265.6% during the fourth quarter. Assenagon Asset Management S.A. now owns 435,049 shares of the company’s stock valued at $179,867,000 after buying an additional 316,048 shares during the period. Clearbridge Investments LLC grew its stake in shares of IDEXX Laboratories by 696.0% during the second quarter. Clearbridge Investments LLC now owns 352,814 shares of the company’s stock valued at $171,891,000 after buying an additional 308,493 shares during the last quarter. Seilern Investment Management Ltd purchased a new position in shares of IDEXX Laboratories in the fourth quarter worth about $113,104,000. Finally, Vontobel Holding Ltd. increased its holdings in shares of IDEXX Laboratories by 3,325.0% in the third quarter. Vontobel Holding Ltd. now owns 220,159 shares of the company’s stock worth $111,229,000 after buying an additional 213,731 shares during the period. 87.84% of the stock is currently owned by institutional investors.

IDEXX Laboratories Stock Performance

Shares of IDXX opened at $432.34 on Friday. The company has a quick ratio of 1.03, a current ratio of 1.42 and a debt-to-equity ratio of 0.32. The stock has a market cap of $35.40 billion, a P/E ratio of 41.69, a P/E/G ratio of 3.60 and a beta of 1.36. The business’s 50 day moving average price is $423.28 and its 200-day moving average price is $456.85. IDEXX Laboratories, Inc. has a 52 week low of $398.50 and a 52 week high of $583.39.

IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Thursday, October 31st. The company reported $2.80 EPS for the quarter, topping the consensus estimate of $2.69 by $0.11. IDEXX Laboratories had a return on equity of 55.42% and a net margin of 22.53%. The business had revenue of $975.50 million for the quarter, compared to the consensus estimate of $980.32 million. During the same period in the previous year, the company posted $2.53 earnings per share. The company’s revenue for the quarter was up 6.6% compared to the same quarter last year. Equities research analysts anticipate that IDEXX Laboratories, Inc. will post 10.44 earnings per share for the current fiscal year.

Insider Buying and Selling at IDEXX Laboratories

In other IDEXX Laboratories news, Director Sophie V. Vandebroek sold 344 shares of IDEXX Laboratories stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total value of $144,631.36. Following the completion of the sale, the director now owns 905 shares of the company’s stock, valued at approximately $380,498.20. This trade represents a 27.54 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 2.11% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

IDXX has been the subject of a number of recent analyst reports. Barclays lowered their price target on shares of IDEXX Laboratories from $570.00 to $481.00 and set an “overweight” rating for the company in a report on Monday, November 4th. Piper Sandler reaffirmed a “neutral” rating and set a $435.00 price target (down previously from $520.00) on shares of IDEXX Laboratories in a research report on Monday, November 4th. StockNews.com upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Thursday, November 28th. JPMorgan Chase & Co. decreased their target price on IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating for the company in a report on Friday, October 11th. Finally, Stifel Nicolaus decreased their price target on shares of IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating for the company in a research note on Thursday, October 10th. Two research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $523.86.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.